Small heat shock proteins (sHSPs) are one of the five families of proteins acting as molecular chaperone. sHSPs possess a universally conserved alpha-crystallin domain, hence, also known as alpha-crystallin family. Mycobacterium tuberculosis (MTB) is an etiological agent of tuberculosis, a disease claiming million of lives every year across the world. MTB has two sHSPs: sHSP16.3 (a 16.3 kDa protein) and Acr2 (a 17.8 kDa protein). Of these, sHSP16.3 has been reported to be crucial for survival of MTB during prolonged period of dormancy, in addition to indispensable role in its growth, virulence and cell wall thickening. Additionally, this mycobacterial protein is also beneficial for host as well. Due to strong immunogenic properties and consistent presence in patients sera, sHSP16.3 has largely been implicated in vaccine development and diagnosis of latent and active infections of MTB in the clinical cases of TB. Recently, our study provided the substantial evidence to exploit this mycobacterial protein as a good drug target for developing novel therapeutic intervention. In the present review, a comprehensive analysis of various attributes of sHSP16.3 has been done and major gaps in area have been highlighted for future course of action.
Introduction

sHSP16.3 is a stress induced protein, not heat induced
Like other members of sHSPs family protein, sHSP16.3 is not a heat induced protein as name implies but it is a hypoxia induced protein [11] . Presence of oxygen [11, 16, 17] , reactive nitrogen intermediates (RNIs) [18] , vitamin C [19] and ingestion of MTB by macrophages have also been reported to upregulate the expression of its gene. Recently, our group demonstrated that when MTB infected murine macrophage is treated with exogenous IFN-g and IL-10, the expression of hspX is significantly modulated [20] .
Sub-cellular location of sHSP16.3
The cellular location of MTB sHSP16.3 is unknown till date, although it appears to be peripherally associated with inner membrane [21] and occurred outside of the cell wall [22] . It was not found in culture supernatant [23, 24] .
Structure of sHSP16.3
After spending more than 20 years (from the first reporting of function of sHSP16.3 in 1996 by Yuan and coworkers), it is very unfortunate that sHSP16.3 could not be crystallized. Thus, crystal structure of sHSP16.3 is still not available. However, in an electron cryomicroscopic examination, sHSP16.3 appeared as a triangular shaped particle consisting of three globules or lobes. On the basis of this finding, it was suggested that sHSP16.3 exists as a nonameric structure consisting of trimer of trimers, with a calculated total mass of 144.9 kD [25] . Later on, Berengian and co-workers (1999) confirmed that sHSP16.3 uses trimers as its building blocks to form a large nine-subunit oligomeric complex [26] . Kennaway and group (2005) showed that sHSP16.3 is a dodameric complex formed by tetrahedral arrangement of dimmers [27] . The way in which a sHSP16.3 oligomeric complex assembled and reassembled is well elucidated. It has been demonstrated that sHSP16.3 nonamers are assembled and reassembled via a stepwise process using trimer and hexamer intermediates [28, 29] . Assembling process is initiated with formation of a dimer through interactions between two subunits of α-crystallin domains followed by further interaction of this dimer to third subunit resulting in formation of an asymmetric trimer. Finally, this asymmetric trimer is assembled into symmetric nonamers through the interactions between N-terminal and C-terminal domains [30] .
sHSP16.3 of MTB is composed of 144 amino acids and has molecular mass of 16, 277 Da [31] . In subsequent time, its molecular mass was found to be 16, 227 Da [32] . The sHSP16.3 polypeptide possesses three domains like other members of sHSPs family proteins, a 85 residues long characteristic α-crystallin domain flanked by a stretch of 41 residues nonconserved N-terminal region followed by 16 residues long conserved C-terminal region [30, 33] .
Immunogenic property MTB sHSP16.3 was initially identified as a 14 kD immunodominant antigen with strong immunogenic properties [31, 34, 35] . Later, monoclonal antibodies studies showed that sHSP16.3 antigen of MTB has specific B -cell [31] and T cells epitopes [36] . The antibody against sHSP16.3 has been found in about 70% of smear-positive patients with pulmonary tuberculosis (PTB) [37] . sHSP16.3 is recognized by both CD4 + and CD8 + T cells [38] [39] [40] . The most immunogenic peptide of sHSP16.3 is the 91-110 bp long sequence, recognized by 50% of the TB patients [36] . Further, it was observed that 91-110 immunogenic domain of sHSP16.3 comprises 91 
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104 sequence which generates strong T cells responses in both human T cell clones and peripheral blood mononuclear cells (PBMCs) [41] . Previously, it was shown that peptide p91-110 contains specific T cells epitopes and exhibited high binding affinity with human leukocyte antigen (HLA)-DR (HLA-DRB1*0101, HLA-DRB1*1501 and HLA-DRB1*0401) [42] . Jurcevic and his co-workers showed that this MTB peptide binds with high affinity to HLA-DR1 and with moderate affinity to DR6 [43] . The peptide p91-110 not only binds to HLA-DR but also to DQ and DP molecules [44] . There are many other peptides such as p21-40 (HLA-DRB1*0401) [39] , p21-29 and p120-128 (both HLA-A*0201) [45] which have been found to be immunogenic like peptide p91-110. Further investigation revealed that peptide p21-40 binds DR4 with only moderate affinity and DR3 with low affinity [43] . These all peptides were permissively recognized by human T cells [39, 45] . It was observed that peptide p91-110 induces Th1 response through interaction with T cells. By contrast, p21-40 peptide stimulates the Th2 cells to produce IL-4 [39] . Thus, sHSP16.3 antigen favours production of both Th1 and Th2 cytokines. In a preliminary study, sHSP16.3 strongly elicited delayed type hypersensitivity (DTH) reaction in both mice and guinea pigs [46] . Available reports suggested that sHSP16.3 also has role in differentiation and proliferation of functionally distinct T helper subsets [39, 42] .
Genomics and expression of hspX
As discussed earlier, sHSP16.3 is encoded by gene hspX (Rv2031c or acr) [10] . This gene which is composed of 435 base pairs is located between acg and Rv2030c genes in MTB genome [32, 47] . However, there is evidence that another gene is also present within this gene [48] . Sequencing analysis suggests that start codon (i.e. ATG) and stop codon (i.e. TGA) are situated at position 16 and 433 respectively in coding region of sHSP16.3. The ShineDalgarno (SD) sequence which is AGGAGG, was located 7 base pairs upstream of the ATG start codon [31] . The hspX gene has only one operon [49] .
The expression of hspX mRNA was found high in log phase MTB. However, its cellular level was gradually decreased with shifting of bacterium to stationary phase [48] . Surprisingly, this decrease in mRNA accumulation whose half life is 2 minutes was accompanied by an increase in its translational rate. When tubercle bacillus is subjected to reverse step i.e. stationary phase to log phase, a rapid increase in the rate of transcription of hspX mRNA was noticed, but the synthesis of sHSP16.3 was remained unaffected, suggesting the presence of posttranscriptional control mechanism in the expression of hspX [48] .
Regulators of hspX expression
Regulator of dormancy survival (DosR or DevR)-DosS-DosT (also known as Rv3133c-Rv3132c-Rv2027c), a bonafide two-component system (TCS) of MTB, is a major regulator that directly regulates the expression of hspX gene [49] . It comprised a response regulator (RR), DevR and two sensor histidine kinases, DosS and DosT which are susceptible to redox state and oxygen respectively [50, 51] . Expression of hspX exclusively depends on dosR but not on the dosS (Rv3132c) sensor histidine kinase [49, 52] . This finding was further [53] . Under the hypoxic stress, both the sensor kinases are autophosphorylated which in turn lead to phosphorylation of response regulator DosR(DevR). Phosphorylated DosR then binds to upstream of hspX promoter DNA causing up-regulation of sHSP16.3 ( Fig.1 ) [54] . The response regulator (DevR) of this two component system was first characterized in a H37RV virulent strain of MTB and found to be differentially expressed in H37RV strain in comparison of H37Ra avirulent strain, thus, it was named devR (differentially expressed in the virulent strain) [50] . However, this nomenclature in subsequent time was changed and devR was renamed dosR (regulator of dormancy survival) on account of its role in regulation of oxygen starvation-induced mycobacterial dormancy response in Mycobacterium bovis BCG [52] . Gene devR is composed of 654 base pairs encoding 217 amino acids translational product known as DevR. It shows homology to member of the NarL/UhpA/FixJ subfamily [50] .
Gene devR alongwith gene hspX and other co-transcribed 48 genes of MTB constitute a DosR/DevR dormancy regulon [54] . Except Mycobacterium leprae, almost all mycobacterial species possess DosR/DevR regulon [55] . The expression of this regulon is induced by a number of environmental stresses including hypoxia, nitric oxide, carbon monoxide, GSNO (NO donor), H 2 O 2 , ethanol, 30 min standing [49, 51, [56] [57] [58] [59] , nutrient starvation [60] and microaerobic and anaerobic conditions [61] . The dosR/ devR regulon is regulated by two component system DosR (DevR)-DosS-DosT. Interestingly, the response regulator DosR/ DevR and senor kinase DosS are also under the control of another transcriptional regulator phoP [62] .
Function of sHSP16.3
Chaperone activity
The chaperone activity is a characteristics feature of sHSPs which attracted considerable attention of the workers from worldwide over the last two decades. Like other sHSPs, mycobacterial sHSP16.3 also exhibited its chaperonin property by preventing the thermal denaturation of alcohol dehydrogenase in vitro [11] . Similar finding was also reported by Chang and co-workers in 1996 [25] . For performing chaperone function, sHSP16.3 exposes its hydrophobic surfaces for interaction with denaturing proteins [63] and undergoes [64] . Disturbance in native structures of sHSP16.3 and presence of amino acid leucine (Leu122) in protein backbone are also essential for chaperone like activity [64, 65] , but ATP is not [11, 25, 63] . Valdez et al. (2002) reported that the presence of ATP in reaction not only enhanced the chaperone activity of MTB sHSP16.3 by two fold but also protects this MTB protein from proteolytic attack of chymotrypsin [66] . Moreover, chaperone activity of MTB sHSP16.3 is exclusively temperature dependent [67] . Even, pre-incubation of sHSP16.3 at 100 0 C resulted in enhanced chaperone like activity without altering the surface hydrophobicity [68] .
Survival of MTB during dormancy sHSP16.3 is a potentially important molecule of MTB, facilitating its survival during long-term dormancy [11, 22, 66, 69] . It is synthesized in low quantity in early exponential phase cultures, but its cellular level increases when bacterium reaches stationary phase. The maximum synthesis of protein was observed during stationary phase [11] . Another study carried out by Hu and Coates (1999) suggested that sHSP16.3 is a stable protein, whose cellular presence was uniform through the culture period from 20 days to 50 days [48] .
Indispensable for growth and virulence of MTB
Gene knockout studies indicated that sHSP16.3 is an inevitable requirement for normal growth of MTB during infection [69, 70] . The deletion of gene hspX of MTB resulted in enhancement of bacterial growth whereas its overexpression slows the bacilli growth during early phase of mice infection. sHSP16.3 is also required for the virulence of MTB [70] .
Cell wall thickening sHSP16.3 has been found to be instrumental in cell wall thickening, thus facilitating dormancy indirectly as the thickened cell wall helps the bacilli to survive the hostile environment of host during actual course of infection [22] .
Usefulness of sHSP16.3 for host
Novel vaccine candidate sHSP16.3 has been widely exploited for enhancing the host immunity against MTB infection. An increasing amount of evidence is available which suggests its application as a novel candidate for vaccine design / formulation. In a number of experimental models, this mycobacterial antigen alongwith other antigens provided high level of protection to host against different phases of tuberculosis infection [13, [71] [72] [73] [74] [75] [76] . However, its clinical application is currently awaited.
Novel diagnostic marker
The three characteristic features i.e. predominance in latency, specificity to MTB complex and frequent occurrence in sera of TB patients make this sHSP16.3 a new hope for clinicians to develop a novel immunodiagnostic strategy for early and rapid diagnosis of the latent infection of MTB in undefined cases of tuberculosis, in addition to its acute infection. There are substantial evidences which suggest that sHSP16.3 is a potent seroand immuno-diagnostic marker for accurate and early diagnosis of MTB in active and latent tuberculosis cases, when used alone or in combination with other MTB antigens [77] [78] [79] [80] .
Novel drug target
The current regimens for treatment of tuberculosis are lengthy, difficult to comply and significantly toxic [81] . Hence, it was felt since long time to develop new and better drugs / therapeutic modalities that would be more effective, shorter in length, tolerable and less toxic. With these goals, a more concerted effort was made during the last decades. As a result, some novel approaches of treatment for TB have been explored. Of these, host-directed therapy (HDT) and re-purposing of existing drugs have attracted considerable attention of the world [81] [82] [83] . Host-directed therapies rely either on the principle of modulating the specific host immune pathways or limiting the collateral tissue damage to be associated with pathogenesis of MTB. Unlike standard TB drugs, this therapeutic modality targets host proteins, hence, there is a lesser chance of development of antibiotic resistance in MTB [82] . In addition, many old drugs including oxazolidinones, β-lactams, clofazimine which were used for other clinical indications have also been repurposed for TB treatment. These repurposed drugs categorized as Group-5 agents by the World Health Organization have shown potential to treat both drug-susceptible and resistant strains of MTB [84] , however, before routine application, their efficacy, dose, schedule, length of treatment, tolerability and toxicity are necessary to re-examine in various clinical settings.
In the way of discovery of new drugs that would be highly specific to MTB, whole genome sequencing of MTB and new computational technologies have played significant role. Today, many novel drug targets including proteins to be involved in amino acid biosynthesis, cofactor biosynthesis, mycothiol biosynthesis, DNA synthesis, glyoxylate shunt, oxidative phosphorylation, menaquinone biosynthesis and terpenoid biosynthesis are well known which are being targeted with both natural and synthetic compounds in order to develop MTB specific drugs [85] [86] [87] [88] [89] [90] . Accumulating evidences also suggested that targeting of two component systems (TCSs) which have central role in the intracellular survival of MTB may be best option for drug discovery [91, 92] .
As mentioned earlier, sHSPs primarily function as a molecular chaperone. In addition, sHSP plays a vital role in growth, survival and virulence of bacteria [93, 94] . As the fact that a sHSP interacts with a number of proteins (of diverse origin and nature) / regulatory partners (co-chaperones) during performing its action as a molecular chaperone; so, targeting a particular sHSP with potential inhibitor may lead to impair the function(s) of proteins supposed to be in its network. This multisite targeting is not possible with other non-sHSP molecules. Hence, these all factors/merits make this protein family a promising drug target. In recent few years, sHSPs have largely been implicated in drug development for developing the drugs of choice for various clinical conditions including cancer. Inhibition of HSP27 with small molecule inhibitors quercetin and RP101 has been proved to be an efficient way in combating the cancer. Of these, RP101 inhibitor is currently under advanced stages of clinical trial. RP101 has been found to be safe with no side-effects for cancer patients [95, 96] . Similar to HSP27, HSP70 and HSP90 have also been emerged as potential drug targets for cancer chemotherapy, although, they do not belong to sHSP family. Various inhibitors have been developed against these HSPs over the last few years and of these, some have entered clinical trials [97] .
Like other sHSPs, the MTB sHSPs were not much explored from the perspectives of drug development. Hence, not much information is available on targeting of these proteins. However, some caseinolytic protein (Clp) group proteins (ClpC1, ClpP1 and ClpP2) which belong to heat shock protein HSP100 family of molecular chaperone and possess inherent ATPase activity [98, 99] have been targeted with a variety of compounds including cyclomarin A [100, 101] , ecumicin [102] , rufomycin [103] , lassomycin [104] , ADEP-2 [105, 106] , N-(2-(3, 5-difluorophenyl)acetyl-Trp-boroMet), N-(Picolinoyl)-Ala-Lys-boroMet [107] and bortezomib (velcade) [108] in the past few years. Although the development of suitable inhibitors against these Clp proteins is in its early stage, the outcome of preliminary studies suggested that these inhibitors may be potential for MTB killing. Our group recently targeted sHSP16.3 using phytocompounds viz. ursolic acid and carvacrol by computational approaches. Findings of molecular docking analysis showed that both phytocompounds have strongly docked with sHSP16.3 and exhibited tendency to block the function of this crucial mycobacterial protein. Further, it was observed that both phytocompounds have strong binding ability to sHSP16.3 during whole 60 ns MD simulation time-frame. To further confirm the stability of protein-ligand complexes, we calculated the molecular [12] . Previously, DevR, regulator of sHSP16.3, was targeted with phenylcoumarin derivative to produce the proof of concept for its importance as a novel drug target. The experimental data demonstrated that phenylcoumarin derivative inhibited the DevR binding to target DNA, down-regulated the expression of genes to be associated with dormancy and reduced the survival of hypoxic MTB [109] .
Existing gaps and Conclusion
Although considerable amount of information is available on MTB dormancy protein sHSP16.3, its mechanism of action in natural state of MTB infection is not known. In addition, its role in evasion of the host-killing immune response has also not been elucidated. In view of the above lacunae, there is a necessity to demonstrate the chaperone function and role of sHSP16.3 in actual condition of infection, host-pathogen interaction and particularly in evasion of host immune mechanisms in vivo, so that further advanced strategy for killing the intracellular MTB using this protein could be developed.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
